
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Therapeutics is a clinical-stage biotechnology company with a positive outlook due to its pioneering program, detalimogene, for patients with Non-Muscle Invasive Bladder Cancer. The company's proprietary Dually Derivatized Oligochitosan platform and promising results from its ongoing multi-cohort LEGEND Phase 2 trial demonstrate potential for future success in addressing high clinical needs. However, the recent lower market share assumptions and lower probability of success for detalimogene in NMIBC raise concerns and may impact the company's valuation. The upcoming AUA plenary presentation and data on the polidocanol bladder rinse cohort will be critical in determining the potential for failure patterns, durability, and progression.
Bears say
enGene Therapeutics is facing a challenging road ahead as the efficacy of its lead drug, detalimogene, has declined significantly in its interim analysis. This decline is particularly driven by recently enrolled patients, indicating a potential lack of consistency in the drug's mechanism of action. Additionally, the company's CMO may be departing, creating further uncertainty for the company's future. As a result, the financial analyst has downgraded enGene Therapeutics to Neutral and has lowered their price target to $6. Further risks to achieving this price target include clinical, regulatory, and competitive factors.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares